How big is the AI clinical documentation market?

What does each estimate actually count?

Three publishers, three markets. Mordor Intelligence puts AI in clinical documentation at $1.15 billion in 2026, up from $0.98 billion in 2025, and projects $3.05 billion by 2031, a compound annual growth rate (CAGR) of 21.46%. Fortune Business Insights puts generative AI for clinical documentation at $1.05 billion in 2026, from $0.79 billion in 2025, rising to $10.50 billion by 2034 at 33.3% a year. The Business Research Company puts clinical documentation improvement at $4.65 billion in 2026, from $4.30 billion, rising to $6.27 billion by 2030 at 7.8% a year.

The names suggest one market measured three times; the scopes say otherwise. Mordor counts any machine-learning, natural-language or automation tool that captures, structures or generates clinical notes, plus the services and hardware sold with them, with ambient scribing the anchor at 53.34% of 2025 application value. Fortune counts generative tools only. The Business Research Company counts a process rather than a technology: the software and consulting that make a medical record accurate and complete enough to code and bill.

This means $1.05 billion, $1.15 billion and $4.65 billion side by side are not a forecast dispute. Two of the figures measure overlapping technology markets; the third measures a services market that AI is only beginning to enter. Any attempt to reconcile two market size estimates starts with this table, before a single number is compared.

The strongest evidence that definition drives the number comes from one publisher. Fortune Business Insights also sizes ambient clinical documentation, at $1.20 billion in 2025 and $1.46 billion in 2026, rising to $7.00 billion by 2034 at 21.6% a year, with implementation and managed services counted alongside software. Same firm, same base year, two perimeters: $1.05 billion against $1.46 billion for 2026, and 33.3% growth against 21.6%.

Why is one estimate four times the others?

Because clinical documentation improvement is mostly not an AI market. The Business Research Company divides it into solutions and consulting services, and the consulting side is labor: CDI program implementation, coding audits and compliance, training and education. Its buyers include health insurers as well as care providers. Its software side includes natural-language CDI tools, which is where the overlap with AI documentation sits.

The growth rate gives the scope away. The publisher's 2025 edition put CDI at $3.99 billion in 2024 and $4.30 billion in 2025; the 2026 edition carries $4.30 billion forward to $4.65 billion. That is a steady single-digit market in both editions. If AI scribes made up most of the $4.65 billion, the total could not grow at 7.8% while every AI estimate grows at 21% or more.

This means the $4.65 billion belongs in an investment case as the adjacent pool, not the starting market. It is where documentation AI vendors want to go next, because coding ties the note to reimbursement; Caspr's Market Research Study of the sector records Oracle Health adding automated coding and chart review to its Clinical AI Agent in August 2026. A thesis that counts CDI spending as a scribe vendor's market today underwrites that expansion as if it had already happened.

Why do the AI estimates agree on size but not on growth?

On size, the two AI estimates sit close together: $1.15 billion and $1.05 billion for 2026, about 9% apart. That gap is definitional, and narrower than the definitions imply, since Mordor's market also holds older speech recognition, non-generative CDI software and hardware that Fortune's definition leaves out.

On growth, they genuinely disagree. Compounded at its stated 33.3% a year from $1.05 billion, the generative segment reaches about $3.3 billion in 2030. Mordor's entire AI documentation market, generative tools included, reaches $3.05 billion only in 2031. A subset cannot outgrow the market that contains it, so the two paths cannot both hold. The difference is not what is counted. It is how fast generative tools displace older speech recognition and spread beyond the outpatient visit.

The slower path has a second witness. Fortune's own ambient market grows at 21.6%, within a fifth of a point of Mordor's 21.46%. Two publishers, two definitions, one rate: the 33.3% belongs to the generative framing alone.

Deployment evidence explains the split. Where conditions suit ambient AI, adoption is fast: Cleveland Clinic reported in August 2025 that more than 4,000 of roughly 6,000 eligible ambulatory physicians and advanced practice providers were actively using its ambient scribe within 15 weeks, for 76% of their scheduled office visits. Where conditions do not, it is slow. In a 2026 emergency department study cited by the Caspr Study, ambient AI was used in 976 of 8,740 eligible encounters, 11.2%, and by only 35 of 92 attending physicians.

This means the low-20s rate is the one already visible in clinic notes. The 33% path needs emergency departments, inpatient wards and coding to adopt at clinic speed, and no deployment evidence yet shows that. Judging whether a market size number is credible comes down to this test: does the growth rate match what buyers are observably doing?

How much of the market can a standalone vendor capture?

Less than the headline suggests. Each estimate counts spending on documentation AI; none says who receives it. Fortune reports that integrated tools, not standalone ones, held the larger share of the generative market in 2025.

On February 4, 2026, Epic rolled out AI Charting, a built-in feature that listens during patient visits, drafts the clinician's note and queues up orders from the conversation. Epic also reported that Art's Insights, its pre-visit chart summary, was in use more than 16 million times a month, nearly three times the November 2025 level. A feature inside the health record reaches clinicians through the record vendor's existing customers. A standalone scribe has to win each health system on its own.

Timing matters for the estimates themselves. Mordor's page states that its figures reflect data as of January 2026, weeks before AI Charting shipped. An estimate dated before February 2026 describes the market before the record vendor's entry; the effect on standalone revenue has to be modeled separately.

This means market size and capturable revenue need separate lines in the model. The Caspr Study reads the field as consolidating around three defensible positions: control of the health record, cross-vendor ambient specialization, and suites that bundle documentation with coding and chart review. Commure's merger with Augmedix, completed in October 2024, is its documented case of a standalone asset absorbed into a suite. In commercial due diligence on a sector, the question after market size is which position the target holds.

Which figure belongs in an investment memo?

The one whose definition matches what the company sells, stated with its publisher, date and scope in the same sentence.

Two errors follow from mixing these figures. The first is blending: quoting $4.65 billion as the market and 33% as its growth joins a services perimeter to a generative-only growth rate, describing a market nobody measures. The second is comparing end points across horizons. $6.27 billion in 2030, $3.05 billion in 2031 and $10.50 billion in 2034 cannot be ranked until they are brought to the same year.

For a US thesis, none of the three publishes a US-only figure on its public page. North America is 50.16% of Mordor's 2025 market, 48.1% of Fortune's generative market ($0.38 billion in 2025) and about 70% of Fortune's ambient market. North America includes Canada, so each share is a ceiling for the US. The spread from 48% to 70% comes from two perimeters at one publisher, which is reason enough to name the perimeter a US figure rests on.

This means the market section of an investment memo on AI clinical documentation needs four sentences: the narrow figure and its definition; the base growth rate and the condition for the upside; the CDI figure, named as adjacent; and who captures the spend. A committee that reads those four has the market opportunity and the main risk to the return in one paragraph.

The published figures

Why the figures differ

• definitional Mordor Intelligence, AI in clinical documentation ($1.15bn) and Fortune Business Insights, generative AI for clinical documentation ($1.05bn), 2026 size Fortune counts generative tools only; Mordor adds older speech recognition, non-generative CDI software, services and hardware. The 9% gap is smaller than the gap in scope.
• definitional The AI-only estimates ($1.05bn and $1.15bn) and The Business Research Company, clinical documentation improvement ($4.65bn), 2026 size CDI counts consulting, coding audits, training and compliance work for providers and insurers, most of it not AI, which is why it grows at 7.8%.
• genuine Fortune Business Insights, generative AI (33.3% a year) and Mordor Intelligence, AI in clinical documentation (21.46% a year), growth At 33.3% from $1.05bn, the generative subset passes $3.05bn in 2030, a year before Mordor's whole AI market does. The disagreement is about pace, not scope.
• definitional Fortune Business Insights, generative AI ($1.05bn, 33.3%) and Fortune Business Insights, ambient clinical documentation ($1.46bn, 21.6%), 2026 One publisher, two perimeters: the ambient market adds implementation and managed services; the generative market counts only generative tools, dictation and summarization included.

Frequently asked

Keep reading

• SaaS revenue multiples: why 8.5x and 3.3x can both be right
• How to defend a market size estimate when the committee challenges it